A case of successful treatment of comorbid obesity and polycystic ovarian disease with add-on metformin in bipolar disorder

Primary Care Companion to the Journal of Clinical Psychiatry

Volumn 13, Issue 5, 2011, Pages

  Agarwal, M ^a   Behere, Rishikesh V ^a   Venkatasubramanian, Ganesan ^a   Rao, Naren P ^a   Varambally, Shivarama ^a   Gangadhar, B N ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH AND NEUROSCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; METFORMIN; QUETIAPINE; RISPERIDONE; THYROTROPIN; THYROXINE;

ADD ON THERAPY; ADULT; BIPOLAR DISORDER; BODY MASS; CASE REPORT; COMORBIDITY; DOSE RESPONSE; DRUG EFFICACY; EXERCISE; FEMALE; HUMAN; LETTER; LIFESTYLE MODIFICATION; MANIA; OBESITY; OLIGOMENORRHEA; OUTCOME ASSESSMENT; OVARY POLYCYSTIC DISEASE; THYROID DISEASE; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 84856055848     PISSN: 15235998     EISSN: 1555211X     Source Type: Journal    
DOI: 10.4088/PCC.11l01164     Document Type: Letter

References (13)

1. Kenna HA, Jiang B, Rasgon NL. Reproductive and metabolic abnormalities associated with bipolar disorder and its treatment. Harv Rev Psychiatry. 2009;17(2):138-146. doi:10.1080/10673220902899722
2. Jiang B, Kenna HA, Rasgon NL. Genetic overlap between polycystic ovary syndrome and bipolar disorder: the endophenotype hypothesis. Med Hypotheses. 2009;73(6):996-1004. doi:10.1016/j.mehy.2008.12.056
3. Haddad PM, Das A, Ashfaq M, et al. A review of valproate in psychiatric practice. Expert Opin Drug Metab Toxicol. 2009;5(5):539-551. doi:10.1517/17425250902911455
4. McIntyre RS, Woldeyohannes HO, Soczynska JK, et al. The rate of metabolic syndrome in euthymic Canadian individuals with bipolar I/II disorder. Adv Ther. 2010;27(11):828-836. doi:10.1007/s12325-010-0072-z
5. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004;19(1):41-47. doi:10.1093/humrep/deh098
6. Marshall AL, Smith BJ, Bauman AE, et al. Reliability and validity of a brief physical activity assessment for use by family doctors. Br J Sports Med. 2005;39(5):294-297. doi:10.1136/bjsm.2004.013771
7. Rassi A, Veras AB, dos Reis M, et al. Prevalence of psychiatric disorders in patients with polycystic ovary syndrome. Compr Psychiatry. 2010;51(6):599-602. doi:10.1016/j.comppsych.2010.02.009
8. Klipstein KG, Goldberg JF. Screening for bipolar disorder in women with polycystic ovary syndrome: a pilot study. J Affect Disord. 2006;91(2-3):205-209. doi:10.1016/j.jad.2006.01.011
9. Magnotti M, Futterweit W. Obesity and the polycystic ovary syndrome. Med Clin North Am. 2007;91(6):1151-1168, ix-x. doi:10.1016/j.mcna.2007.06.010
10. Pramyothin P, Khaodhiar L. Metabolic syndrome with the atypical antipsychotics. Curr Opin Endocrinol Diabetes Obes. 2010;17(5):460-466. doi:10.1097/MED.0b013e32833de61c
11. Diamanti-Kandarakis E, Economou F, Palimeri S, et al. Metformin in polycystic ovary syndrome. Ann N Y Acad Sci. 2010;1205:192-198.
12. Wu RR, Zhao JP, Jin H, et al. Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial. JAMA. 2008;299(2):185-193. doi:10.1001/jama.2007.56-b
13. Babić D, Maslov B, Martinac M, et al. Bipolar disorder and metabolic syndrome: comorbidity or side effects of treatment of bipolar disorder. Psychiatr Danub. 2010;22(1):75-78.